XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Earnings for XBiotech Inc. (XBIT)
Earnings in 2023 (TTM): $-24,313,000
According to XBiotech Inc.'s latest financial reports the company's current earnings (TTM) are $-24,313,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of XBiotech Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-24,313,000 | $-24,557,000 |
| 2022 | $-33,588,000 | $-32,900,000 |
| 2021 | $-25,458,000 | $-17,414,000 |
| 2020 | $-12,827,000 | $-11,221,000 |
| 2019 | $718.45 M | $668.63 M |
| 2018 | $-21,138,000 | $-21,138,000 |
| 2017 | $-33,150,000 | $-33,150,000 |
| 2016 | $-52,761,000 | $-52,761,000 |
| 2015 | $-37,483,000 | $-37,483,000 |
| 2014 | $-21,724,000 | $-21,724,000 |
| 2013 | $-9,927,000 | $-9,927,000 |
| 2012 | $-15,160,000 | $-15,160,000 |